Cinclus Pharma

CINPHA · ST · Healthcare / Drug Manufacturers - Specialty & Generic

11.58SEK+0.16 (+1.40%)

Price History

Full chart

Market Stats

Previous Close11.42

Open11.48

Day Range11.48 – 11.78

52-Week Range10.48 – 19.64

Volume27.01K

Market Cap602.20M

P/E (TTM)0.00

Forward P/E0.00

EPS-5.33

Dividend Yield0.00%

Beta-0.03

50-Day Avg12.36

200-Day Avg14.36

About

Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori. Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden.

Company Details

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CEOMr. Christer Ahlberg
Employees17
HeadquartersKungsbron 1, Elevator G, Stockholm, Sweden, 11122, Sweden
Websitehttps://cincluspharma.com

Leadership

Dr. Lennart Hansson Ph.D.Co-founder & Chairman of the Board · b. 1956
Mr. Christer AhlbergCEO & President · b. 1971
Mr. Peter UngeCo-founder & Member of Scientific Advisory Board · b. 1951
Mr. Magnus ChristensenChief Financial Officer · b. 1974
Ms. Kajsa LarssonChief Medical Officer · b. 1966
Mr. Jesper WiklundChief Business Officer · b. 1969
Mr. Peter WallichChief Commercial Officer & Commercial Director · b. 1961
Dr. Margit Mahlapuu Ph.D.Executive R&D Director · b. 1972

Financials

Income Statement

Currency: SEK	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	10.57M	5.96M	4.58M	57.47M
Growth (%)	-	-43.63%	-23.14%	+1154.80%
Operating Income	-210.73M	-200.28M	-168.93M	-198.18M
Operating Margin	-1993.45%	-3360.98%	-3688.45%	-344.84%
EBITDA	-229.82M	-205.91M	-157.22M	-180.94M
EBITDA Margin	-2174.06%	-3455.53%	-3432.69%	-314.84%
Net Income	-249.07M	-215.12M	-168.03M	-183.97M
Net Income Margin	-2356.20%	-3609.97%	-3668.80%	-320.12%
R&D	157.18M	166.68M	136.66M	198.40M
R&D as % of Total Revenue	1486.94%	2797.08%	2983.78%	345.23%
Interest Expense	76.00K	7.45M	8.73M	395.00K
Interest Expense % of Total Revenue	0.72%	124.97%	190.52%	0.69%

Balance Sheet

Currency: SEK	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	185.77M	94.41M	601.01M	546.56M
Total Liabilities	58.90M	171.21M	45.68M	177.16M
Total Equity	126.87M	-76.80M	555.33M	369.39M
Cash	173.55M	87.97M	566.72M	487.25M
Net Debt	-	42.37M	-	-

Cash Flow

Currency: SEK	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-192.08M	-209.19M	-178.37M	-74.65M
Capital Expenditure	0	0	0	1.13M
Free Cash Flow	-192.08M	-209.19M	-178.37M	-75.78M
FCF to OCF	100.00%	100.00%	100.00%	101.52%

Earnings

Report Date	Aug 29, 2024	Nov 14, 2024	Feb 20, 2025	May 20, 2025	Jun 30, 2025	Sep 30, 2025	Dec 31, 2025	Mar 31, 2026	Jun 30, 2026
EPS Estimate	-	-	-	-	-	-	-	-	-
EPS Actual	-1.41	-0.79	-1.17	-0.72	-1.04	-0.87	-1.31	-1.91	-1.69
Surprise	-	-	-	-	-	-	-	-	-
Timing	Pre-market	Pre-market	Pre-market	Pre-market	-	-	-	-	-

Key Statistics & Ratios

Market Cap602.20M

Enterprise Value213.11M

Trailing P/E0.00

Forward P/E0.00

Price / Sales17.12

Price / Book2.70

EPS-5.33

Book Value4.36

Revenue (TTM)35.18M

Gross Profit (TTM)35.18M

EBITDA-289.57M

Profit Margin0.00%

Operating Margin-5381.14%

Return on Equity-79.92%

Return on Assets-34.71%

Shares Outstanding46.54M

Shares Float34.29M

Beta-0.03

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%